International Biotechnology (LON:IBT) Stock Price Passes Above Two Hundred Day Moving Average – Time to Sell?

International Biotechnology (LON:IBT)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 686.23 ($8.48) and traded as high as GBX 710 ($8.77). International Biotechnology shares last traded at GBX 710 ($8.77), with a volume of 48,839 shares traded.

International Biotechnology Stock Performance

The company has a quick ratio of 0.32, a current ratio of 0.46 and a debt-to-equity ratio of 9.66. The firm has a market capitalization of £262.42 million, a P/E ratio of 1,479.17 and a beta of 0.21. The stock has a fifty day moving average of GBX 693.15 and a 200-day moving average of GBX 686.23.

International Biotechnology (LON:IBT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported GBX (9.16) (($0.11)) earnings per share (EPS) for the quarter. International Biotechnology had a return on equity of 6.25% and a net margin of 75.33%. On average, research analysts anticipate that International Biotechnology will post 0.9435943 EPS for the current year.

International Biotechnology Increases Dividend

The business also recently declared a dividend, which will be paid on Friday, January 24th. Shareholders of record on Thursday, December 19th will be paid a GBX 15.56 ($0.19) dividend. This represents a yield of 2.21%. This is an increase from International Biotechnology’s previous dividend of $14.50. The ex-dividend date of this dividend is Thursday, December 19th. International Biotechnology’s dividend payout ratio (DPR) is currently 6,041.67%.

Insider Buying and Selling at International Biotechnology

In other International Biotechnology news, insider Katherine Cornish-Bowden bought 1,500 shares of International Biotechnology stock in a transaction dated Tuesday, December 17th. The stock was bought at an average cost of GBX 713 ($8.81) per share, for a total transaction of £10,695 ($13,210.23). Corporate insiders own 4.18% of the company’s stock.

International Biotechnology Company Profile

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.